The company utilizes proprietary drug discovery platforms to develop differentiated medicines that are highly potent and act selectively on validated targets. Arisaph currently has several active drug discovery programs in various stages of development. Arisaph employs rational drug design approaches to develop differentiated new chemical entities (NCEs) that are highly potent and act on select, validated targets. By focusing its drug development activities on validated targets, the Company believes that the risks associated with new chemical entity development can be mitigated compared with developing first-in-class compounds for nonvalidated targets.
Arisaph Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on developing novel therapies for cardiometabolic diseases and cancer.